Market Size of North America Mammography Industry
Study Period | 2021 - 2029 |
Base Year For Estimation | 2023 |
Forecast Data Period | 2024 - 2029 |
Market Size (2024) | USD 1.18 Billion |
Market Size (2029) | USD 1.83 Billion |
CAGR (2024 - 2029) | 9.21 % |
Major Players*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
North America Mammography Market Analysis
The North America Mammography Market size is estimated at USD 1.18 billion in 2024, and is expected to reach USD 1.83 billion by 2029, growing at a CAGR of 9.21% during the forecast period (2024-2029).
The COVID-19 pandemic has had a substantial impact on the mammography market initially. The strict lockdowns and government regulations that were intended to slow down the spread of COVID-19 resulted in a decrease in diagnostic activities for breast cancer. For instance, an article published by RSNA in October 2021, stated that during the early pandemic many breast imaging practices purposefully halted mammographic screening in the United States to minimize patient and staff exposure to the virus, which led to a disruption in breast cancer diagnosis rate. Furthermore, according to a joint statement by the American College of Radiology and the American Society of Breast Surgeons published in March 2020, all medical facilities in the United States were asked to postpone breast screening exams including screening mammography, ultrasound, and MRI. Currently, the mammography market has recovered but it still has not gained growth like the pre-pandemic period. For instance, an article published by PubMed Central in June 2022, stated that COVID-19 had the greatest impact on screening mammography volumes in the United States, which have not recovered to pre-COVID-19 levels yet. The article further stated that cancer diagnoses declined significantly in the acute phase of the pandemic and have not fully rebounded, which emphasizes the need to increase outreach efforts directed at the specific patient population and facility types in the United States. Hence, the COVID-19 pandemic had a significant impact on the studied market, and it is expected that the market would gain traction slowly as the COVID-19 pandemic subsides completely during the forecast period of the study.
The rising incidence of breast cancer, massive R&D in breast cancer therapies, and advances in breast imaging modalities are the major drivers of this market. Apart from these factors, the investment from various organizations in breast cancer screening campaigns also boosts the market growth. According to the updated data by CDC in 2022, breast cancer is one of the most common cancers among women, irrespective of race or ethnicity. According to same source, each year an estimated 264,000 new cases of breast cancer are diagnosed in women and about 2,400 in men in the United States. Furthermore, the Society of Breast Imaging in the United States is an organization that focuses on minimizing breast cancer's impact and saving patients' lives. They have a research & education fund program that aims at providing funds to support the research and education for breast imaging.
In addition, new product launches and strategic activities by major players in the market are positively affecting the growth of the studied market. For example, in October 2022, The American College of Radiology (ACR) launched the Contrast-Enhanced Mammography Imaging Screening Trial (CMIST) in collaboration with the Breast Cancer Research Foundation (BCRF) and GE Healthcare. The trial will determine whether contrast-enhanced mammography improves breast cancer detection rate and reduce false-positive exams in women with dense breasts. Furthermore, in November 2021, Lunit, a leading medical AI provider in North America, launched 'Lunit INSIGHT MMG' a mammography solution for breast cancer detection after it received United States FDA clearance.
Therefore, owing to the aforementioned factors, the studied market is anticipated to witness growth over the analysis period. However, the risk of adverse effects from radiation exposure is likely to impede the market's growth.